Global pharmaceutical company
Appears in 8 stories · Last updated Oct 29, 2026
Won FDA approval on October 26, 2026 for use in earlier-stage, HRR-mutated prostate cancer
The Food and Drug Administration approved talazoparib (Talzenna) plus enzalutamide (Xtandi) on October 26 for men whose metastatic prostate cancer carries mutations in DNA-repair genes and who have not yet started hormone therapy for castration-resistant disease. The clearance moves the pair into the earlier castration-sensitive stage, where the trial showed it cut the risk of the cancer spreading or the patient dying by 52%.
Updated Oct 29
Licensee running global pivotal Phase III program
At the 2026 European Society for Medical Oncology congress, 3SBio reported a median progression-free survival (the time patients live without the disease worsening) of 13.6 months in squamous and 13.8 months in non-squamous advanced lung cancer. The drug, tivunatamig, was combined with chemotherapy, and the control groups received tislelizumab plus chemotherapy, reaching 8.3 and 9.7 months.
As of October 2026: Maker of Prevnar 20, a comparator in OPUS-1
Vaxcyte said Monday its experimental pneumococcal vaccine met every primary goal in the first of three late-stage trials. VAX-31, which targets 31 strains of the bacteria behind pneumonia and meningitis, matched Pfizer's Prevnar 20 and Merck's Capvaxive on nearly all shared strains, beat both on three strains only it covers, and sent shares up roughly 50% to push the company's market value past $12 billion.
Updated Oct 7
As of August 2026: Awaiting the EMA's review outcome; has not yet confirmed submitting its FDA Biologics License Application, previously targeted for 2026
The vaccine, now formally designated PF-07307405 (also called LB6V, and previously known as VLA15), cleared its first regulatory hurdle since March's Phase 3 results. On August 14, 2026, the European Medicines Agency validated Pfizer and Valneva's marketing application, meaning the dossier is complete and formal review can begin.
Updated Aug 15
As of August 2026: Developer of oral ritlecitinib for vitiligo
For most of medical history, vitiligo had no fix. Doctors could sometimes slow the spreading white patches, but regrowing lost skin color was mostly out of reach.
Updated Aug 5
As of July 2026: Competitor whose Paxlovid failed as a prevention drug
For years, the only move after a close COVID-19 exposure was to wait and watch for symptoms. Now there is a pill for that.
Updated Jul 29
As of May 2026: Co-developer; seeking third-party commercialization partner
For 25 years, drug companies have tried to design medicines that destroy harmful proteins outright rather than blocking them. On May 1, the U.S. Food and Drug Administration (FDA) approved the first one.
Updated May 31
As of May 2026: Donating antibiotics through 2030
For the first time since records began, fewer than 100 million people need treatment for trachoma—a bacterial eye disease that's been blinding humans since ancient Egyptian times. The number at risk has cratered 94% since 2002, from 1.5 billion to 97 million. Twenty-seven countries have eliminated it entirely, making trachoma one of the success stories celebrated at World NTD Day 2026 on January 30.
Updated May 20
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
